Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBIT (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed EBIT for 5 consecutive years, with $102.0 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 96.07% to $102.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$36.0 million through Dec 2025, down 2168.33% year-over-year, with the annual reading at -$36.0 million for FY2025, 2168.33% down from the prior year.
  • EBIT hit $102.0 million in Q4 2025 for ARS Pharmaceuticals, up from -$53.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $102.0 million in Q4 2025 to a low of -$53.2 million in Q3 2025.
  • Historically, EBIT has averaged -$5.0 million across 5 years, with a median of -$16.7 million in 2022.
  • Biggest YoY gain for EBIT was 397.08% in 2023; the steepest drop was 224.76% in 2023.
  • Year by year, EBIT stood at $46.6 million in 2021, then plummeted by 133.12% to -$15.4 million in 2022, then soared by 397.08% to $45.9 million in 2023, then increased by 13.39% to $52.0 million in 2024, then skyrocketed by 96.07% to $102.0 million in 2025.
  • Business Quant data shows EBIT for SPRY at $102.0 million in Q4 2025, -$53.2 million in Q3 2025, and -$47.6 million in Q2 2025.